Janssen’s Tremfya approved for active psoriatic arthritis
Tremfya is a first-in-class treatment for the disease, shown to improve disease measures and quality of life
Read More
Author: Selina McKee
Mixed reaction to chancellor’s spending review
Chancellor Rishi Sunak hands out extra £3 billion to NHS and £14.6 billion in funding for R&D
Read More
NHS launches 40 ‘long COVID’ clinics
It is hoped that the move will help to tackle the persistent symptoms – such as fatigue and brain fog – suffered by people who have developed the condition
Read More
£12.2m boost for coronavirus genomic surveillance
The funds will help expand the scale of SARS-CoV-2 virus sequencing in the hope of revealing new opportunities for intervention
Read More
J&J launches second PhIII COVID-19 trial
Janssen will enrol participants in countries with high incidence of COVID-19, including the UK
Read More- NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma
- Anocca doses first patients with precision TCR‑T therapy
- Connecta launches phase 2a trial of neuroplasticity modulator
- Aquipta recommended by NICE for acute migraine treatment
- Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
